| Year |
Citation |
Score |
| 2022 |
Meister H, Look T, Roth P, Pascolo S, Sahin U, Lee S, Hale BD, Snijder B, Regli L, Ravi V, Heiland DH, Sentman CL, Weller M, Weiss T. Multifunctional mRNA-based CAR T cells display promising anti-tumor activity against glioblastoma. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 36037304 DOI: 10.1158/1078-0432.CCR-21-4384 |
0.468 |
|
| 2022 |
Brog RA, Ferry SL, Schiebout CT, Messier CM, Cook WJ, Abdullah L, Zou J, Kumar P, Sentman CL, Frost HR, Huang YH. Superkine IL2 and IL33 armored CAR T cells reshape the tumor microenvironment and reduce growth of multiple solid tumors. Cancer Immunology Research. PMID 35696724 DOI: 10.1158/2326-6066.CIR-21-0536 |
0.497 |
|
| 2021 |
Butler SE, Brog RA, Chang CH, Sentman CL, Huang YH, Ackerman ME. Engineering a natural ligand-based CAR: directed evolution of the stress-receptor NKp30. Cancer Immunology, Immunotherapy : Cii. PMID 34046711 DOI: 10.1007/s00262-021-02971-y |
0.439 |
|
| 2020 |
Cook WJ, Choi Y, Gacerez A, Bailey-Kellogg C, Sentman CL. A Chimeric Antigen Receptor That Binds to a Conserved Site on MICA. Immunohorizons. 4: 597-607. PMID 33037097 DOI: 10.4049/immunohorizons.2000041 |
0.462 |
|
| 2020 |
Godbersen-Palmer C, Coupet TA, Grada Z, Zhang SC, Sentman CL. Toxicity Induced by a Bispecific T Cell-Redirecting Protein Is Mediated by Both T Cells and Myeloid Cells in Immunocompetent Mice. Journal of Immunology (Baltimore, Md. : 1950). PMID 32295875 DOI: 10.4049/jimmunol.1901401 |
0.473 |
|
| 2019 |
Godbersen-Palmer C, Coupet T, Grada Z, Sentman C. Abstract 1542: Bispecific T cell engager-induced toxicity in an immunocompetent solid tumor model Cancer Research. 79: 1542-1542. DOI: 10.1158/1538-7445.Am2019-1542 |
0.574 |
|
| 2019 |
Coupet TA, Godbersen-Palmer C, Sentman CL. Abstract 1539: Mechanisms of action of bispecific T cell engager-mediated immune response in a lymphoma tumor model Cancer Research. 79: 1539-1539. DOI: 10.1158/1538-7445.Am2019-1539 |
0.558 |
|
| 2019 |
Weiss T, Meister H, Weller M, Sentman C, Roth P. IMMU-17. TARGETING GLIOBLASTOMA WITH DNAM-1-BASED CHIMERIC ANTIGEN RECEPTOR (CAR) T CELLS Neuro-Oncology. 21: vi122-vi122. DOI: 10.1093/Neuonc/Noz175.510 |
0.602 |
|
| 2019 |
Weiss T, Meister H, Weller M, Sentman C, Roth P. PL2.1 Exploiting the DNAM-1 system for chimeric antigen receptor (CAR) T cell therapy of glioblastoma Neuro-Oncology. 21: iii2-iii2. DOI: 10.1093/Neuonc/Noz126.002 |
0.615 |
|
| 2018 |
Baumeister SH, Murad J, Werner L, Daley H, Trebeden-Negre H, Gicobi JK, Schmucker A, Reder J, Sentman CL, Gilham DE, Lehmann FF, Galinsky I, DiPietro H, Cummings K, Munshi NC, et al. Phase 1 Trial of Autologous CAR T Cells Targeting NKG2D Ligands in Patients with AML/MDS and Multiple Myeloma. Cancer Immunology Research. PMID 30396908 DOI: 10.1158/2326-6066.Cir-18-0307 |
0.483 |
|
| 2018 |
Murad JM, Baumeister SH, Werner L, Daley H, Trébéden-Negre H, Reder J, Sentman CL, Gilham D, Lehmann F, Snykers S, Sentman ML, Wade T, Schmucker A, Fanger MW, Dranoff G, et al. Manufacturing development and clinical production of NKG2D chimeric antigen receptor-expressing T cells for autologous adoptive cell therapy. Cytotherapy. 20: 952-963. PMID 30180944 DOI: 10.1016/J.Jcyt.2018.05.001 |
0.487 |
|
| 2018 |
Murad JM, Graber DJ, Sentman CL. Advances in the use of natural receptor- or ligand-based chimeric antigen receptors (CARs) in haematologic malignancies. Best Practice & Research. Clinical Haematology. 31: 176-183. PMID 29909918 DOI: 10.1016/j.beha.2018.03.003 |
0.39 |
|
| 2018 |
Gacerez AT, Sentman CL. T-bet promotes potent antitumor activity of CD4CAR T cells. Cancer Gene Therapy. PMID 29515240 DOI: 10.1038/S41417-018-0012-7 |
0.622 |
|
| 2018 |
Gacerez AT, Hua CK, Ackerman ME, Sentman CL. Chimeric antigen receptors with human scFvs preferentially induce T cell anti-tumor activity against tumors with high B7H6 expression. Cancer Immunology, Immunotherapy : Cii. PMID 29453518 DOI: 10.1007/s00262-018-2124-1 |
0.466 |
|
| 2017 |
Weiss T, Weller M, Guckenberger M, Sentman CL, Roth P. NKG2D-based CAR-T cells and radiotherapy exert synergistic efficacy in glioblastoma. Cancer Research. PMID 29222400 DOI: 10.1158/0008-5472.Can-17-1788 |
0.609 |
|
| 2017 |
Hua CK, Gacerez AT, Sentman CL, Ackerman ME. Development of unique cytotoxic chimeric antigen receptors based on human scFv targeting B7H6. Protein Engineering, Design & Selection : Peds. 1-9. PMID 29040754 DOI: 10.1093/protein/gzx051 |
0.504 |
|
| 2017 |
Demoulin B, Cook WJ, Murad J, Graber DJ, Sentman ML, Lonez C, Gilham DE, Sentman CL, Agaugue S. Exploiting natural killer group 2D receptors for CAR T-cell therapy. Future Oncology (London, England). PMID 28613086 DOI: 10.2217/fon-2017-0102 |
0.477 |
|
| 2017 |
Godbersen C, Coupet TA, Huehls AM, Zhang T, Battles MB, Fisher JL, Ernstoff MS, Sentman CL. NKG2D ligand targeted Bispecific T Cell Engagers lead to robust antitumor activity against diverse human tumors. Molecular Cancer Therapeutics. PMID 28500232 DOI: 10.1158/1535-7163.MCT-16-0846 |
0.552 |
|
| 2017 |
Weiss T, Weller M, Pruschy M, Sentman C, Roth P. OS09.3 Synergistic activity of NKG2D-based chimeric antigen receptor (CAR)-T cells and radiotherapy against glioma Neuro-Oncology. 19: iii18-iii18. DOI: 10.1093/Neuonc/Nox036.062 |
0.52 |
|
| 2017 |
Sentman CL. Preclinical Studies in CAR T Cell Development Clinical Lymphoma Myeloma and Leukemia. 17: S205-S207. DOI: 10.1016/j.clml.2017.08.092 |
0.401 |
|
| 2016 |
Sentman ML, Murad JM, Cook WJ, Wu MR, Reder J, Baumeister SH, Dranoff G, Fanger MW, Sentman CL. Mechanisms of Acute Toxicity in NKG2D Chimeric Antigen Receptor T Cell-Treated Mice. Journal of Immunology (Baltimore, Md. : 1950). PMID 27849169 DOI: 10.4049/Jimmunol.1600769 |
0.849 |
|
| 2016 |
Arellano B, Graber DJ, Sentman CL. Regulatory T cell-based therapies for autoimmunity. Discovery Medicine. 22: 73-80. PMID 27585233 |
0.375 |
|
| 2016 |
Smits NC, Coupet TA, Godbersen C, Sentman CL. Designing multivalent proteins based on natural killer cell receptors and their ligands as immunotherapy for cancer. Expert Opinion On Biological Therapy. PMID 27248342 DOI: 10.1080/14712598.2016.1195364 |
0.55 |
|
| 2016 |
Rajasekaran K, Riese MJ, Rao S, Wang L, Thakar MS, Sentman CL, Malarkannan S. Signaling in Effector Lymphocytes: Insights toward Safer Immunotherapy. Frontiers in Immunology. 7: 176. PMID 27242783 DOI: 10.3389/Fimmu.2016.00176 |
0.409 |
|
| 2016 |
Gacerez AT, Arellano B, Sentman CL. How Chimeric Antigen Receptor Design Affects Adoptive T Cell Therapy. Journal of Cellular Physiology. PMID 27163336 DOI: 10.1002/Jcp.25419 |
0.553 |
|
| 2016 |
Smits NC, Sentman CL. Bispecific T-Cell Engagers (BiTEs) as Treatment of B-Cell Lymphoma. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. PMID 26884583 DOI: 10.1200/Jco.2015.64.9970 |
0.49 |
|
| 2016 |
Nikiforow S, Murad J, Daley H, Negre H, Reder J, Sentman CL, Lehmann F, Snykers S, Allen R, Galinsky I, Munshi NC, Stone RM, Soiffer R, Ritz J, Baumeister SH. A first-in-human phase I trial of NKG2D chimeric antigen receptor-T cells in AML/MDS and multiple myeloma. Journal of Clinical Oncology. 34: TPS3102-TPS3102. DOI: 10.1200/Jco.2016.34.15_Suppl.Tps3102 |
0.596 |
|
| 2016 |
Nikiforow S, Werner L, Murad J, Jacobs M, Johnston L, Patches S, White R, Daley H, Negre H, Reder J, Sentman C, Wade T, Schmucker A, Lehmann FF, Snykers S, et al. Safety Data from a First-in-Human Phase 1 Trial of NKG2D Chimeric Antigen Receptor-T Cells in AML/MDS and Multiple Myeloma Blood. 128: 4052-4052. DOI: 10.1182/Blood.V128.22.4052.4052 |
0.525 |
|
| 2016 |
Daley H, Nikiforow S, Murad J, Negre H, Reider J, Sentman C, Snykers S, Allen R, Galinsky I, Munshi N, Stone R, Soiffer R, Ritz J, Baumeister S. 71. Validation of Manufacturing NKG2D Chimeric Antigen Receptor T Cells for a First-In-Human Clinical Trial in AML/MDS and Multiple Myeloma Molecular Therapy. 24: S31. DOI: 10.1016/S1525-0016(16)32880-5 |
0.62 |
|
| 2015 |
Gowen BG, Chim B, Marceau CD, Greene TT, Burr P, Gonzalez JR, Hesser CR, Dietzen PA, Russell T, Iannello A, Coscoy L, Sentman CL, Carette JE, Muljo SA, Raulet DH. A forward genetic screen reveals novel independent regulators of ULBP1, an activating ligand for natural killer cells. Elife. 4. PMID 26565589 DOI: 10.7554/Elife.08474 |
0.565 |
|
| 2015 |
Choi Y, Hua C, Sentman CL, Ackerman ME, Bailey-Kellogg C. Antibody humanization by structure-based computational protein design. Mabs. 7: 1045-57. PMID 26252731 DOI: 10.1080/19420862.2015.1076600 |
0.303 |
|
| 2015 |
Wu MR, Zhang T, Gacerez AT, Coupet TA, DeMars LR, Sentman CL. B7H6-Specific Bispecific T Cell Engagers Lead to Tumor Elimination and Host Antitumor Immunity. Journal of Immunology (Baltimore, Md. : 1950). 194: 5305-11. PMID 25911747 DOI: 10.4049/Jimmunol.1402517 |
0.857 |
|
| 2015 |
Wu MR, Zhang T, DeMars LR, Sentman CL. B7H6-specific chimeric antigen receptors lead to tumor elimination and host antitumor immunity. Gene Therapy. PMID 25830550 DOI: 10.1038/Gt.2015.29 |
0.841 |
|
| 2015 |
Wu MR, Zhang T, Alcon A, Sentman CL. DNAM-1-based chimeric antigen receptors enhance T cell effector function and exhibit in vivo efficacy against melanoma. Cancer Immunology, Immunotherapy : Cii. 64: 409-18. PMID 25549845 DOI: 10.1007/S00262-014-1648-2 |
0.838 |
|
| 2015 |
Stephan SB, Taber AM, Jileaeva I, Pegues EP, Sentman CL, Stephan MT. Biopolymer implants enhance the efficacy of adoptive T-cell therapy. Nature Biotechnology. 33: 97-101. PMID 25503382 DOI: 10.1038/Nbt.3104 |
0.532 |
|
| 2015 |
Huehls AM, Coupet TA, Sentman CL. Bispecific T-cell engagers for cancer immunotherapy. Immunology and Cell Biology. 93: 290-6. PMID 25367186 DOI: 10.1038/Icb.2014.93 |
0.598 |
|
| 2015 |
Gowen BG, Chim B, Marceau CD, Greene TT, Burr P, Gonzalez JR, Hesser CR, Dietzen PA, Russell T, Iannello A, Coscoy L, Sentman CL, Carette JE, Muljo SA, Raulet DH. Author response: A forward genetic screen reveals novel independent regulators of ULBP1, an activating ligand for natural killer cells Elife. DOI: 10.7554/Elife.08474.033 |
0.366 |
|
| 2014 |
Wu MR, Cook WJ, Zhang T, Sentman CL. Targeting multiple types of tumors using NKG2D-coated iron oxide nanoparticles. Nanotechnology. 25: 475101. PMID 25371538 DOI: 10.1088/0957-4484/25/47/475101 |
0.802 |
|
| 2014 |
Sentman CL, Meehan KR. NKG2D CARs as cell therapy for cancer. Cancer Journal (Sudbury, Mass.). 20: 156-9. PMID 24667963 DOI: 10.1097/Ppo.0000000000000029 |
0.61 |
|
| 2014 |
Talebian L, Fischer DA, Wu J, Channon JY, Sentman CL, Ernstoff MS, Meehan KR. The natural killer-activating receptor, NKG2D, on CD3+CD8+ T cells plays a critical role in identifying and killing autologous myeloma cells. Transfusion. 54: 1515-21. PMID 24446786 DOI: 10.1111/Trf.12517 |
0.523 |
|
| 2014 |
Spear P, Barber A, Rynda-Apple A, Sentman CL. Correction: Chimeric Antigen Receptor T Cells Shape Myeloid Cell Function within the Tumor Microenvironment through IFN-γ and GM-CSF The Journal of Immunology. 193: 1513.4-1513. DOI: 10.4049/jimmunol.1490025c |
0.856 |
|
| 2014 |
Barber A, Rynda A, Sentman CL. Correction: Chimeric NKG2D Expressing T Cells Eliminate Immunosuppression and Activate Immunity within the Ovarian Tumor Microenvironment The Journal of Immunology. 193: 1513.3-1513. DOI: 10.4049/jimmunol.1490025b |
0.815 |
|
| 2013 |
Sentman CL. Challenges of creating effective chimeric antigen receptors for cancer therapy. Immunotherapy. 5: 783-5. PMID 23902543 DOI: 10.2217/Imt.13.71 |
0.547 |
|
| 2013 |
Spear P, Wu MR, Sentman ML, Sentman CL. NKG2D ligands as therapeutic targets. Cancer Immunity. 13: 8. PMID 23833565 |
0.796 |
|
| 2013 |
Spear P, Barber A, Sentman CL. Collaboration of chimeric antigen receptor (CAR)-expressing T cells and host T cells for optimal elimination of established ovarian tumors. Oncoimmunology. 2: e23564. PMID 23734311 DOI: 10.4161/Onci.23564 |
0.86 |
|
| 2013 |
Spear P, Barber A, Rynda-Apple A, Sentman CL. NKG2D CAR T-cell therapy inhibits the growth of NKG2D ligand heterogeneous tumors. Immunology and Cell Biology. 91: 435-40. PMID 23628805 DOI: 10.1038/Icb.2013.17 |
0.854 |
|
| 2013 |
Zhang T, Sentman CL. Mouse tumor vasculature expresses NKG2D ligands and can be targeted by chimeric NKG2D-modified T cells. Journal of Immunology (Baltimore, Md. : 1950). 190: 2455-63. PMID 23355740 DOI: 10.4049/Jimmunol.1201314 |
0.612 |
|
| 2013 |
Meehan KR, Talebian L, Tosteson TD, Hill JM, Szczepiorkowski Z, Sentman CL, Ernstoff MS. Adoptive cellular therapy using cells enriched for NKG2D+CD3+CD8+T cells after autologous transplantation for myeloma. Biology of Blood and Marrow Transplantation : Journal of the American Society For Blood and Marrow Transplantation. 19: 129-37. PMID 22975165 DOI: 10.1016/J.Bbmt.2012.08.018 |
0.45 |
|
| 2012 |
Zhang T, Wu MR, Sentman CL. An NKp30-based chimeric antigen receptor promotes T cell effector functions and antitumor efficacy in vivo. Journal of Immunology (Baltimore, Md. : 1950). 189: 2290-9. PMID 22851709 DOI: 10.4049/Jimmunol.1103495 |
0.85 |
|
| 2012 |
Spear P, Barber A, Rynda-Apple A, Sentman CL. Chimeric antigen receptor T cells shape myeloid cell function within the tumor microenvironment through IFN-γ and GM-CSF. Journal of Immunology (Baltimore, Md. : 1950). 188: 6389-98. PMID 22586039 DOI: 10.4049/Jimmunol.1103019 |
0.865 |
|
| 2011 |
Iyori M, Zhang T, Pantel H, Gagne BA, Sentman CL. TRAIL/DR5 plays a critical role in NK cell-mediated negative regulation of dendritic cell cross-priming of T cells. Journal of Immunology (Baltimore, Md. : 1950). 187: 3087-95. PMID 21832159 DOI: 10.4049/Jimmunol.1003879 |
0.572 |
|
| 2011 |
Talebian L, Wu JY, Fischer DA, Hill JM, Szczepiorkowski ZM, Ernstoff MS, Sentman CL, Meehan KR. Novel mobilization strategies to enhance autologous immune effector cells in multiple myeloma. Frontiers in Bioscience (Elite Edition). 3: 1500-8. PMID 21622154 DOI: 10.2741/E351 |
0.497 |
|
| 2011 |
Barber A, Sentman CL. NKG2D receptor regulates human effector T-cell cytokine production. Blood. 117: 6571-81. PMID 21518928 DOI: 10.1182/Blood-2011-01-329417 |
0.792 |
|
| 2011 |
Zhang T, Sentman CL. Cancer immunotherapy using a bispecific NK receptor fusion protein that engages both T cells and tumor cells. Cancer Research. 71: 2066-76. PMID 21282338 DOI: 10.1158/0008-5472.Can-10-3200 |
0.674 |
|
| 2011 |
Barber A, Meehan KR, Sentman CL. Treatment of multiple myeloma with adoptively transferred chimeric NKG2D receptor-expressing T cells. Gene Therapy. 18: 509-16. PMID 21209626 DOI: 10.1038/Gt.2010.174 |
0.825 |
|
| 2010 |
Meehan KR, Talebian L, Wu J, Hill JM, Szczepiorkowski ZM, Sentman CL, Ernstoff MS. Immune mobilization of autologous blood progenitor cells: direct influence on the cellular subsets collected. Cytotherapy. 12: 1013-21. PMID 20873991 DOI: 10.3109/14653249.2010.515580 |
0.485 |
|
| 2010 |
Kopcow HD, Eriksson M, Mselle TF, Damrauer SM, Wira CR, Sentman CL, Strominger JL. Human decidual NK cells from gravid uteri and NK cells from cycling endometrium are distinct NK cell subsets. Placenta. 31: 334-8. PMID 20172608 DOI: 10.1016/J.Placenta.2010.01.003 |
0.81 |
|
| 2010 |
Talebian L, Meehan K, Patey ME, Fisher DA, Szczepiorkowski Z, Ernstoff M, Sentman C. NKG2D, An NK Cell Activating Receptor on CD8+ T Cells, Plays An Essential Role In Killing Myeloma Cells Blood. 116: 2087-2087. DOI: 10.1182/Blood.V116.21.2087.2087 |
0.513 |
|
| 2009 |
Barber A, Rynda A, Sentman CL. Chimeric NKG2D expressing T cells eliminate immunosuppression and activate immunity within the ovarian tumor microenvironment. Journal of Immunology (Baltimore, Md. : 1950). 183: 6939-47. PMID 19915047 DOI: 10.4049/Jimmunol.0902000 |
0.846 |
|
| 2009 |
Mselle TF, Howell AL, Ghosh M, Wira CR, Sentman CL. Human uterine natural killer cells but not blood natural killer cells inhibit human immunodeficiency virus type 1 infection by secretion of CXCL12. Journal of Virology. 83: 11188-95. PMID 19692460 DOI: 10.1128/Jvi.00562-09 |
0.765 |
|
| 2009 |
Barber A, Sentman CL. Chimeric NKG2D T cells require both T cell- and host-derived cytokine secretion and perforin expression to increase tumor antigen presentation and systemic immunity. Journal of Immunology (Baltimore, Md. : 1950). 183: 2365-72. PMID 19625653 DOI: 10.4049/Jimmunol.0900721 |
0.839 |
|
| 2009 |
Cubillos-Ruiz JR, Engle X, Scarlett UK, Martinez D, Barber A, Elgueta R, Wang L, Nesbeth Y, Durant Y, Gewirtz AT, Sentman CL, Kedl R, Conejo-Garcia JR. Polyethylenimine-based siRNA nanocomplexes reprogram tumor-associated dendritic cells via TLR5 to elicit therapeutic antitumor immunity. The Journal of Clinical Investigation. 119: 2231-44. PMID 19620771 DOI: 10.1172/Jci37716 |
0.791 |
|
| 2009 |
Kalkunte SS, Mselle TF, Norris WE, Wira CR, Sentman CL, Sharma S. Vascular endothelial growth factor C facilitates immune tolerance and endovascular activity of human uterine NK cells at the maternal-fetal interface. Journal of Immunology (Baltimore, Md. : 1950). 182: 4085-92. PMID 19299706 DOI: 10.4049/Jimmunol.0803769 |
0.779 |
|
| 2009 |
Basu S, Eriksson M, Pioli PA, Conejo-Garcia J, Mselle TF, Yamamoto S, Wira CR, Sentman CL. Human uterine NK cells interact with uterine macrophages via NKG2D upon stimulation with PAMPs. American Journal of Reproductive Immunology (New York, N.Y. : 1989). 61: 52-61. PMID 19086992 DOI: 10.1111/J.1600-0897.2008.00661.X |
0.784 |
|
| 2009 |
Talebian LX, Fischer DA, Szczepiorkowski ZM, Sentman CL, Meehan KR. The Critical Requirement of the NKG2D Receptor On CD8+ T Cells in Killing Myeloma Cells. Blood. 114: 4733-4733. DOI: 10.1182/Blood.V114.22.4733.4733 |
0.601 |
|
| 2009 |
Kakarla S, Shaffer D, Ahmed N, Wang L, Lee D, Sentman C, Gottschalk S. T-Cells Redirected Against NKG2D-Ligands for the Immunotherapy of Osteosarcoma Biology of Blood and Marrow Transplantation. 15: 82-83. DOI: 10.1016/J.Bbmt.2008.12.255 |
0.522 |
|
| 2008 |
Huarte E, Cubillos-Ruiz JR, Nesbeth YC, Scarlett UK, Martinez DG, Buckanovich RJ, Benencia F, Stan RV, Keler T, Sarobe P, Sentman CL, Conejo-Garcia JR. Depletion of dendritic cells delays ovarian cancer progression by boosting antitumor immunity. Cancer Research. 68: 7684-91. PMID 18768667 DOI: 10.1158/0008-5472.Can-08-1167 |
0.465 |
|
| 2008 |
Basu S, Pioli PA, Conejo-Garcia J, Wira CR, Sentman CL. Estradiol regulates MICA expression in human endometrial cells. Clinical Immunology (Orlando, Fla.). 129: 325-32. PMID 18728002 DOI: 10.1016/J.Clim.2008.07.005 |
0.799 |
|
| 2008 |
Barber A, Zhang T, Megli CJ, Wu J, Meehan KR, Sentman CL. Chimeric NKG2D receptor-expressing T cells as an immunotherapy for multiple myeloma. Experimental Hematology. 36: 1318-28. PMID 18599182 DOI: 10.1016/J.Exphem.2008.04.010 |
0.838 |
|
| 2008 |
Kalkunte S, Chichester CO, Gotsch F, Sentman CL, Romero R, Sharma S. Evolution of non-cytotoxic uterine natural killer cells. American Journal of Reproductive Immunology (New York, N.Y. : 1989). 59: 425-32. PMID 18405313 DOI: 10.1111/J.1600-0897.2008.00595.X |
0.517 |
|
| 2008 |
Meehan KR, Wu J, Webber SM, Barber A, Szczepiorkowski ZM, Sentman C. Development of a clinical model for ex vivo expansion of multiple populations of effector cells for adoptive cellular therapy. Cytotherapy. 10: 30-7. PMID 18202972 DOI: 10.1080/14653240701762398 |
0.781 |
|
| 2008 |
Barber A, Zhang T, Sentman CL. Immunotherapy with chimeric NKG2D receptors leads to long-term tumor-free survival and development of host antitumor immunity in murine ovarian cancer. Journal of Immunology (Baltimore, Md. : 1950). 180: 72-8. PMID 18097006 DOI: 10.4049/Jimmunol.180.1.72 |
0.826 |
|
| 2008 |
Barber MA, Zhang T, Gagne BA, Van Ginderachter JA, De Baetselier P, Sentman CL. Ly49G2 receptor blockade reduces tumor burden in a leukemia model but not in a solid tumor model. Cancer Immunology, Immunotherapy : Cii. 57: 655-62. PMID 17891395 DOI: 10.1007/S00262-007-0404-2 |
0.544 |
|
| 2008 |
Meehan KR, Hill JM, Ernstoff M, Sentman CL. Immune Mobilization with IL-2 and Growth Factors: Differential in Vivo Effects of the NKG2D Receptor on CD8+ and CD56+ Effector Cells Blood. 112: 3491-3491. DOI: 10.1182/Blood.V112.11.3491.3491 |
0.482 |
|
| 2007 |
Zhang T, Barber A, Sentman CL. Chimeric NKG2D modified T cells inhibit systemic T-cell lymphoma growth in a manner involving multiple cytokines and cytotoxic pathways. Cancer Research. 67: 11029-36. PMID 18006849 DOI: 10.1158/0008-5472.Can-07-2251 |
0.835 |
|
| 2007 |
Mselle TF, Meadows SK, Eriksson M, Smith JM, Shen L, Wira CR, Sentman CL. Unique characteristics of NK cells throughout the human female reproductive tract. Clinical Immunology (Orlando, Fla.). 124: 69-76. PMID 17524808 DOI: 10.1016/J.Clim.2007.04.008 |
0.808 |
|
| 2007 |
Barber A, Zhang T, DeMars LR, Conejo-Garcia J, Roby KF, Sentman CL. Chimeric NKG2D receptor-bearing T cells as immunotherapy for ovarian cancer. Cancer Research. 67: 5003-8. PMID 17510432 DOI: 10.1158/0008-5472.Can-06-4047 |
0.828 |
|
| 2007 |
Barber MA, Zhang T, Gagne BA, Sentman CL. NK cells negatively regulate antigen presentation and tumor-specific CTLs in a syngeneic lymphoma model. Journal of Immunology (Baltimore, Md. : 1950). 178: 6140-7. PMID 17475840 DOI: 10.4049/Jimmunol.178.10.6140 |
0.623 |
|
| 2007 |
Sentman CL, Wira CR, Eriksson M. NK cell function in the human female reproductive tract. American Journal of Reproductive Immunology (New York, N.Y. : 1989). 57: 108-15. PMID 17217364 DOI: 10.1111/J.1600-0897.2006.00448.X |
0.51 |
|
| 2007 |
Grundy MA, Zhang T, Sentman CL. NK cells rapidly remove B16F10 tumor cells in a perforin and interferon-gamma independent manner in vivo. Cancer Immunology, Immunotherapy : Cii. 56: 1153-61. PMID 17160409 DOI: 10.1007/S00262-006-0264-1 |
0.572 |
|
| 2007 |
Hill JM, Wu J, Webber SM, Root LD, Kimtis EA, Williams IC, Ernstoff MS, Szczepiorkowski ZM, Sentman CL, Meehan KR. Immune Mobilization with Direct In-Vivo Effector Response: Clinical Trial with Favorable Implications for Post-Transplant Outcome. Blood. 110: 5120-5120. DOI: 10.1182/Blood.V110.11.5120.5120 |
0.368 |
|
| 2006 |
Eriksson M, Meadows SK, Wira CR, Sentman CL. Endogenous transforming growth factor-beta inhibits toll-like receptor mediated activation of human uterine natural killer cells. American Journal of Reproductive Immunology (New York, N.Y. : 1989). 56: 321-8. PMID 17076676 DOI: 10.1111/J.1600-0897.2006.00432.X |
0.425 |
|
| 2006 |
Grundy MA, Sentman CL. Immunodeficient mice have elevated numbers of NK cells in non-lymphoid tissues. Experimental Cell Research. 312: 3920-6. PMID 17005178 DOI: 10.1016/J.Yexcr.2006.08.019 |
0.546 |
|
| 2006 |
Sentman CL, Barber MA, Barber A, Zhang T. NK cell receptors as tools in cancer immunotherapy. Advances in Cancer Research. 95: 249-92. PMID 16860660 DOI: 10.1016/S0065-230X(06)95007-6 |
0.837 |
|
| 2006 |
Wahle JA, Paraiso KH, Costello AL, Goll EL, Sentman CL, Kerr WG. Cutting edge: dominance by an MHC-independent inhibitory receptor compromises NK killing of complex targets. Journal of Immunology (Baltimore, Md. : 1950). 176: 7165-9. PMID 16751359 DOI: 10.4049/Jimmunol.176.12.7165 |
0.449 |
|
| 2006 |
Zhang T, Barber A, Sentman CL. Generation of antitumor responses by genetic modification of primary human T cells with a chimeric NKG2D receptor. Cancer Research. 66: 5927-33. PMID 16740733 DOI: 10.1158/0008-5472.Can-06-0130 |
0.847 |
|
| 2006 |
Eriksson M, Meadows SK, Basu S, Mselle TF, Wira CR, Sentman CL. TLRs mediate IFN-gamma production by human uterine NK cells in endometrium. Journal of Immunology (Baltimore, Md. : 1950). 176: 6219-24. PMID 16670332 DOI: 10.4049/Jimmunol.176.10.6219 |
0.795 |
|
| 2006 |
Meadows SK, Eriksson M, Barber A, Sentman CL. Human NK cell IFN-gamma production is regulated by endogenous TGF-beta. International Immunopharmacology. 6: 1020-8. PMID 16644489 DOI: 10.1016/J.Intimp.2006.01.013 |
0.757 |
|
| 2005 |
Grundy M, Sentman CL. GFP transgenic mice show dynamics of lung macrophages. Experimental Cell Research. 310: 409-16. PMID 16171803 DOI: 10.1016/J.Yexcr.2005.08.007 |
0.356 |
|
| 2005 |
Usherwood EJ, Meadows SK, Crist SG, Bellfy SC, Sentman CL. Control of murine gammaherpesvirus infection is independent of NK cells. European Journal of Immunology. 35: 2956-61. PMID 16134085 DOI: 10.1002/Eji.200526245 |
0.447 |
|
| 2005 |
Wira CR, Fahey JV, Sentman CL, Pioli PA, Shen L. Innate and adaptive immunity in female genital tract: cellular responses and interactions. Immunological Reviews. 206: 306-35. PMID 16048557 DOI: 10.1111/J.0105-2896.2005.00287.X |
0.429 |
|
| 2005 |
Zhang T, Lemoi BA, Sentman CL. Chimeric NK-receptor-bearing T cells mediate antitumor immunotherapy. Blood. 106: 1544-51. PMID 15890688 DOI: 10.1182/Blood-2004-11-4365 |
0.684 |
|
| 2004 |
Sentman CL, Meadows SK, Wira CR, Eriksson M. Recruitment of uterine NK cells: induction of CXC chemokine ligands 10 and 11 in human endometrium by estradiol and progesterone. Journal of Immunology (Baltimore, Md. : 1950). 173: 6760-6. PMID 15557169 DOI: 10.4049/Jimmunol.173.11.6760 |
0.551 |
|
| 2004 |
Eriksson M, Meadows SK, Wira CR, Sentman CL. Unique phenotype of human uterine NK cells and their regulation by endogenous TGF-beta. Journal of Leukocyte Biology. 76: 667-75. PMID 15178706 DOI: 10.1189/Jlb.0204090 |
0.501 |
|
| 2001 |
Sjöström A, Eriksson M, Cerboni C, Johansson MH, Sentman CL, Kärre K, Höglund P. Acquisition of external major histocompatibility complex class I molecules by natural killer cells expressing inhibitory Ly49 receptors. The Journal of Experimental Medicine. 194: 1519-30. PMID 11714758 DOI: 10.1084/jem.194.10.1519 |
0.431 |
|
| 2001 |
Fahlén L, Lendahl U, Sentman CL. MHC class I-Ly49 interactions shape the Ly49 repertoire on murine NK cells. Journal of Immunology (Baltimore, Md. : 1950). 166: 6585-92. PMID 11359811 DOI: 10.4049/jimmunol.166.11.6585 |
0.383 |
|
| 2001 |
Kambayashi T, Michaëlsson J, Fahlén L, Chambers BJ, Sentman CL, Kärre K, Ljunggren HG. Purified MHC class I molecules inhibit activated NK cells in a cell-free system in vitro. European Journal of Immunology. 31: 869-75. PMID 11241292 DOI: 10.1002/1521-4141(200103)31:3<869::Aid-Immu869>3.0.Co;2-A |
0.357 |
|
| 2000 |
Oberg L, Eriksson M, Fahlén L, Sentman CL. Expression of Ly49A on T cells alters the threshold for T cell responses. European Journal of Immunology. 30: 2849-56. PMID 11069066 DOI: 10.1002/1521-4141(200010)30:10<2849::AID-IMMU2849>3.0.CO;2-6 |
0.445 |
|
| 2000 |
Fahlén L, Oberg L, Brännström T, Khoo NK, Lendahl U, Sentman CL. Ly49A expression on T cells alters T cell selection. International Immunology. 12: 215-22. PMID 10653857 DOI: 10.1093/intimm/12.2.215 |
0.497 |
|
| 2000 |
Eriksson M, Ryan JC, Nakamura MC, Sentman CL. Ly49A inhibitory receptors redistribute on natural killer cells during target cell interaction. Immunology. 97: 341-7. PMID 10447751 DOI: 10.1046/j.1365-2567.1999.00800.x |
0.485 |
|
| 1999 |
Eriksson M, Leitz G, Fällman E, Axner O, Ryan JC, Nakamura MC, Sentman CL. Inhibitory receptors alter natural killer cell interactions with target cells yet allow simultaneous killing of susceptible targets. The Journal of Experimental Medicine. 190: 1005-12. PMID 10510090 DOI: 10.1084/jem.190.7.1005 |
0.387 |
|
| 1998 |
Khoo NKS, Fahlén L, Sentman CL. Modulation of Ly49A receptors on mature cells to changes in major histocompatibility complex class I molecules Immunology. 95: 126-131. PMID 9767467 DOI: 10.1046/j.1365-2567.1998.00577.x |
0.451 |
|
| 1998 |
Cilio CM, Daws MR, Malashicheva A, Sentman CL, Holmberg D. Cytotoxic T lymphocyte antigen 4 is induced in the thymus upon in vivo activation and its blockade prevents anti-CD3-mediated depletion of thymocytes. The Journal of Experimental Medicine. 188: 1239-46. PMID 9763603 DOI: 10.1084/Jem.188.7.1239 |
0.324 |
|
| 1997 |
Fahlén L, Khoo NKS, Daws MR, Sentman CL. Location-specific regulation of transgenic Ly49A receptors by major histocompatibility complex class I molecules European Journal of Immunology. 27: 2057-2065. PMID 9295045 DOI: 10.1002/eji.1830270833 |
0.479 |
|
| 1997 |
Höglund P, Sundbäck J, Olsson-Alheim MY, Johansson M, Salcedo M, Ohlén C, Ljunggren HG, Sentman CL, Kärre K. Host MHC class I gene control of NK-cell specificity in the mouse. Immunological Reviews. 155: 11-28. PMID 9059879 DOI: 10.1111/j.1600-065X.1997.tb00936.x |
0.405 |
|
| 1996 |
Sentman CL, Olsson-Alheim MY, Lendahl U, Kärre K. Influence of glycosylphosphatidylinositol-linked H-2Dd molecules on target cell protection and natural killer cell specificity in transgenic mice. European Journal of Immunology. 26: 2127-32. PMID 8814257 DOI: 10.1002/eji.1830260925 |
0.398 |
|
| 1995 |
Olsson MY, Kärre K, Sentman CL. Altered phenotype and function of natural killer cells expressing the major histocompatibility complex receptor Ly-49 in mice transgenic for its ligand. Proceedings of the National Academy of Sciences of the United States of America. 92: 1649-53. PMID 7878033 DOI: 10.1073/pnas.92.5.1649 |
0.391 |
|
| 1995 |
Sentman CL, Olsson MY, Kärre K. Missing self recognition by natural killer cells in MHC class I transgenic mice. A 'receptor calibration' model for how effector cells adapt to self. Seminars in Immunology. 7: 109-19. PMID 7579193 DOI: 10.1006/smim.1995.0015 |
0.323 |
|
| 1995 |
Linette G, Hess J, Sentman C, Korsmeyer S. Peripheral T-cell lymphoma in lckpr-bcl-2 transgenic mice Blood. 86: 1255-1260. DOI: 10.1182/blood.V86.4.1255.bloodjournal8641255 |
0.409 |
|
| 1992 |
Sentman CL, Shutter JR, Hockenbery D, Kanagawa O, Korsmeyer SJ. bcl-2 inhibits multiple forms of apoptosis but not negative selection in thymocytes. Cell. 67: 879-88. PMID 1835668 DOI: 10.1016/0092-8674(91)90361-2 |
0.324 |
|
| 1991 |
Sentman CL, Kumar V, Bennett M. Rejection of bone marrow cell allografts by natural killer cell subsets: 5E6+ cell specificity for Hh-1 determinant 2 shared by H-2d and H-2f. European Journal of Immunology. 21: 2821-8. PMID 1718761 DOI: 10.1002/eji.1830211125 |
0.31 |
|
| 1989 |
Sentman CL, Hackett J, Kumar V, Bennett M. Identification of a subset of murine natural killer cells that mediates rejection of Hh-1d but not Hh-1b bone marrow grafts. The Journal of Experimental Medicine. 170: 191-202. PMID 2664068 DOI: 10.1084/jem.170.1.191 |
0.444 |
|
| Show low-probability matches. |